Feb. 20, 2025 -- The FDA has approved a new fast-acting insulin biosimilar to help manage blood sugar in people with diabetes, including children and adults. The product, called Merilog ...

The US Food and Drug Administration (FDA) has approved Sanofi’s Merilog (insulin-aspart-szjj), a biosimilar to Novolog (insulin aspart), for treating adults and children with diabetes.

It calls the new drug “Merilog,” a biosimilar to the widely-used insulin product Novolog (insulin aspart). READ: Stem cells show promise in reversing type 1 diabetes The FDA defines a ...

Merilog is available in a 3 mL prefilled pen and a 10 mL vial, joining two long-acting insulin biosimilars approved by the FDA in 2021. Merilog, a rapid-acting human insulin analog, is the first ...

By providing quality-proven biosimilars, we are helping to address a critical healthcare need and reduce the burden of skeletal fractures that impact patients’ quality of life,” said Byoungin ...